Seminar 6: Materials, Health / Pharma / Life Sciencs / Biotech, 3D Printing

  • AM Session : MATERIALS
    • March 3, 2016
      • 9:15 am - 9:30 amFindhan Strain - Composites Manufacturing Consultant, Belfast Metropolitan CollegePresentation Title: The Development of Composite Products in Ireland. Presentation Synopsis: The presentation will focus on a brief overview of the composites market in Ireland, how Belfast Met can assist in designing and manufacturing composite products, case studies for aerospace and industrial applications as well as making the transition from other materials to composites.
      • 9:30 am - 9:45 amAdrian Kinkaid - CEO, MIP Diagnostics.Presentation Title: Introducing nanoMIPs or “Plastic Antibodies” Presentation Synopsis: This presentation will describe a novel technology for the production of a polymer based affinity reagent: the nanoMIP sometimes referred to as a “plastic antibody”. NanoMIPs are nanostructured polymer particles each imprinted with a single high affinity binding site for the target. They are the next generation of affinity reagents based on established molecularly imprinted polymer science. Additional functional groups such as fluorophores and electrochemical sensors can be added to nanoMIPs without interference with the target binding site. Being plastic they are very robust and resilient: they do not require cold storage like protein agents such as antibodies and can withstand extremes of pH and exposure to high levels of solvent making them specially suited to home diagnostics and field based testing including environmental and agrichem applications. Virtually any target type is suitable for nanoMIP development from small molecules such as drugs or vitamins, through peptides and proteins to macromolecular structures such as viruses. NanoMIPs are self-assembly polymers which use the target itself as the template to create a complementary binding pocket without being restricted to a base scaffold with concomitant limitations of size and overall shape. Furthermore given that we can develop a new nanoMIP to a given target in as little as two weeks they also offer enviable speed of development. Example data from case studies using nanoMIPs will also be presented.
      • 9:45 am - 10:00 amAnnaik Genson - R & D Consultancy Manager, Crest (DIT)Presentation Title: Coating expertise, services and solutions for industry. Presentation Synopsis: The CREST Technology Gateway provides access to the research and testing resources within the Dublin Institute of Technology. CREST provides a range of technical and consultancy services on surface coatings to a wide range of industry sectors including Engineering, Automotive, Aerospace and Medical Devices. CREST is also an approval laboratory for NRA and the DAFM for example. This presentation will provide delegates with an overview of the services offered by CREST which aims to build strong partnerships with industry.
      • 10:00 am - 10:15 amDeclan Devine - Director, Materials Research, AITPresentation Title: Polymer research and its importance to the Irish manufacturing industry. Presentation Synopsis: Polymer and plastics materials are of critical importance to the Irish economy. The plastics sector in Ireland accounts for 179 firms which employs 6,500 people which is 4% of the total Irish manufacturing workforce. However, these figures do not include the medical device sector which itself is heavily reliant on the polymer sector as up to 80% of all medical devices are made of or contain polymer components. This sector consists of 400+ companies, employing 27,000 people. The combined exports for these sectors if ca 10 Billion annually. Athlone Institute of Technology has been training polymer graduates since the 1970’s and has conducted research in this field since the 1980’s. Its current research activities are undertaken by the Materials Research Institute (MRI) and its industry focused research centres, the Enterprise Ireland funded Technology Gateway Centre ‘Applied Polymer Technologies (APT) and the Centre for Industrial Services and design. Combined the MRI contribute to ca 100 research projects with Industry annually while offering assistance and advice to many more. The MRI has a core focus on polymer materials, drug delivery technologies, thermoplastic composites, product design, additive manufacturing, construction and renewable materials and biomedical polymers in addition to providing contract and bespoke testing for industrial partners. During the symposium these core competences will be illustrated with reference to industrial cases studies and the use of additive manufacturing to produce mid volume parts will be explored.
      • 10:20 am - 10:50 amCoffee Break and Networking
    PM Session : HEALTH / PHARMA / LIFE SCIENCS / BIOTECH
    • March 3, 2016
      • 10:50 am - 11:05 amPJ Moloney - CEO, EireChrom/EireBioPresentation Title: Trends in Upstream and Downstream Process Development for BioPharmaceutical Manufacturing, and the role of Analytical Characterisation, Qualification and Control
      • 11:05 am - 11:20 amDairine Dempsey – Vice President, Strategic Regulatory Affairs, ICONPresentation Title: “Innovations and regulations in clinical trials – constraints & challenges” Presentation Synopsis: The talk will cover an introduction to ICON plc, an international clinical research organisation running global clinical trials on behalf of the pharmaceutical industry, followed by a brief overview of the regulation of clinical research. Recognising that in modern clinical research there is a significant move towards or at least interest in the use of e-technologies, we will look at an example of an innovative technology developed to facilitate clinical research and review the challenges presented by clinical trials regulations to the successful implementation of innovations in the real world setting.
      • 11:20 am - 11:35 amBrian Harrison - Managing Director, Hitech HealthPresentation Title: Technical Receipt – Streamlining Technical Transfer. Presentation Synopsis: One of the greatest challenges for drug development and supply is the technical transfer of the drug from the site of development to the site of commercial manufacture (and transfer to a second commercial site). No profit can be made until the drug is commercially manufactured, yet this transfer and registration process can take up to three years. The multiple functions (quality, regulatory, technical, manufacturing), the numerous communication methods and the loss of both codified and experiential knowledge add to the complexity and can cause delays in this process. After managing many global technical transfers and experiencing the challenges and frustrations of this process, Hitech Health has developed an integrated software platform ‘Tech Receipt’ that can simplify and streamline the process of embedding technology at the site of commercial manufacture. The talk will outline this platform and its capabilities.
      • 11:35 am - 11:50 amPaul Anglim - Programme Manager at BioInnovate Ireland, Part-time Lecturer, NUI GalwayPresentation Title: Needs Lead Innovation, a multi-disciplinary approach
      • 11:50 am - 12:05 pmDarren Cunningham - Co-Founder and Chief Executive Officer, Inflection BiosciencesPresentation Title: ‘Inflection Biosciences: Innovative Cancer Biotech Start Up’ Presentation Synopsis: Darren Cunningham, Co-Founder and CEO, presents the commercial led business model taken by 2014 Biotech Startup of the Year Inflection Biosciences Ltd. In the presentation Darren will discuss how this approach may be a good model for Ireland Inc to pursue in expanding the indigenous biotech base in Ireland. He will also provide an overview of the innovative targeted therapeutics being developed by the company.
      • 12:05 pm - 12:20 pmRobert O’Connor - Head of Research, Irish Cancer SocietyPresentation Title: “Our health is our wealth”-The relevance of health research to our future.
      • 12:20 pm - 1:20 pmLunch and Networking
      • 1:20 pm - 1:35 pmJess Walsh - Research Nurse, School of Nursing, Midwifery and Health Systems, University College DublinPresentation Title: eHealth: Monitoring Patients undergoing Chemotherapy Using Mobile Phone Technology Presentation Synopsis: UCD School of Nursing, Midwifery and Health Systems are, in partnership with the University of Surrey, conducting a Randomised Controlled Trial within four Irish Hospitals, trialling eSMART (electronic Symptom Management using Advanced Remote Technology). The mobile device allows patients who are undergoing chemotherapy to enter in their symptoms on a daily basis. This information is sent to a secure server, processed, and clinicians are alerted if there are areas of concern. If appropriate, patients then receive a call from their clinician in order to assess the patients symptoms and act on them as necessary. The UCD team are part of the wider trial network, working across 14 European sites, enrolling over 1100 participants.
      • 1:35 pm - 1:50 pmJames McRedmond - Chief Scientific Officer, Java Clinical Research LtdPresentation Title: Helping drug development with better data in early phase clinical trials. Presentation Synopsis: Pharmaceutical development is an expensive business, with no drug certain of progressing through the various stages of clinical trials. Java Clinical Research uses sophisticated laboratory procedures to give detailed, targeted data on drug actions and side effects in early clinical studies. This approach can show clinical proof-of-concept, provide pathway or mechanism data, or address potential side-effects in small studies in human subjects. Such data can help with fundraising, study design or regulatory issues before getting to expensive phase III clinical trials.
      • 1:50 pm - 2:05 pmHarriet Doig – Information, Advocacy and Research Officer, Multiple Sclerosis Society of IrelandPresentation Title: “Multiple Sclerosis research in Ireland in 2016”. Presentation Synopsis: She will give an overview of the projects that MS Ireland is currently supporting and funding, including physiotherapy research at the University of Limerick, demyelination research at NUI Galway and recent report on the societal costs of Multiple Sclerosis.
      • 2:05 pm - 2:20 pmDr. Joanna Griffin - Rotunda HospitalPresentation Title: 270 years of Innovation at The Rotunda Hospital Presentation Synopsis: How innovations at The Rotunda have changed maternity care over the lifetime of the oldest working maternity hospital in the world.
      • 2:20 pm - 2:35 pmBrendan Cunniffe - Managing Director, Prelude Medical Ltd.Presentation Title: Innovative Designs vs. Designing Innovatively: where does your Competitive Advantage lie?
      • 2:35 pm - 2:50 pmCoffee Break and Networking
      • 2:50 pm - 3:05 pmDr Kieran Moran - Health & Human Performance, DCUPresentation Title: Technology enabled behavioural change as a PATHway to better self-management of Cardiovascular Disease Presentation Synopsis: Cardiovascular disease is a leading cause of premature death. While exercise-based cardiac rehabilitation (CR) improves mortality and morbidity rates, uptake is very low. PATHway [H2020, €4.9m] uses behavior change theory and an internet-enabled, sensor-based platform to promote home-based exercising, either by one-self or in a small socially connected group.
      • 3:05 pm - 3:20 pmStefan Buzoianu - Business Development Manager Animal Health/Nutrition, AnaBio Technologies LtdPresentation Title: “Encapsulation for ingredient optimisation in food, feed and pharma”.
    PM Session : 3D PRINTING
    • March 3, 2016
      • 3:20 pm - 3:35 pmTríona Kennedy - ‎Senior Project Manager, Stryker OrthopaedicsPresentation Synopsis: The presentation highlights Stryker as a whole, the depth and breadth of what we do; focuses in on Stryker Ireland and then presents Stryker’s work on Additive Manufacturing.
      • 3:35 pm - 3:50 pmBarry Aldwell - Postdoctoral Research Fellow , TCD Presentation Title: The application of Cold Spray as an additive manufacturing process Presentation Synopsis: Cold Spray shows great potential for use as an additive manufacturing process. With Cold Spray it is possible to manufacture metal components at build rates exceeding 250 g/min, with densities of greater than 95%, with no heat affected zone or changes in the microstructure of the feedstock. It is also possible to create composite materials by mixing powders, and to join materials which are not metallurgically compatible. This presentation will detail the potential application areas for cold spray, highlighting some areas where the innovative use of Cold Spray allows for the creation of components and assemblies which would not be possible using other thermal spray or manufacturing processes.
      • 3:50 pm - 4:05 pmTony Flanagan - Business Development Manager, SCHIVO 3DPresentation Title: From rapid prototyping to additive manufacturing: the evolution of 3D printing. Presentation Synopsis: Looking at how 3D printing has evolved from a prototyping technology to the point where the Airbus A350 XWB aircraft contains over 1,000 3D printed parts and the developments that have driven this evolution
      • 4:05 pm - 4:20 pmDr. Ramesh Raghavendra – SEAM Centre Director, Waterford Institute of TechnologyPresentation Title: Metal 3D Printing: How SEAM can assist Manufacturing Industries in Ireland? Presentation Synopsis: An industry dedicated materials research and development facility, SEAM (South Eastern Applied Materials) Research Centre located at Waterford Institute of Technology, has been a success story in expanding opportunities in the Medical device, Precision Engineering, Pharma and Energy Sectors in Ireland. SEAM, currently seed funded under Enterprise Ireland’s Technology Gateway programme, has established itself as the first stop for companies seeking assistance on materials related issues that cannot be solved by utilising their on-site resources. SEAM’s metallic, polymer and ceramic experience are proving invaluable to its clients due to offerings of its niche technologies (X-ray CT scan, Metal 3D printing & Finite Element Modelling) and materials research capabilities to resolve their day to day process/product and quality related issues. SEAM has an impeccable track record of delivering for industry, having executed over 900 direct funded industry projects spanning across over 110 companies since its launch in 2009. This talk predominantly focuses on SEAM’s 3D Metal Additive Manufacturing capability and how it can assist industries in design, prototype and validation of component parts.
      • 4:20 pm - 4:35 pmDermot Brabazon - Associate Professor, Mechanical and Manufacturing Engineering, DCUPresentation Title: Industrial applications of and developments in additive manufacturing technologies. Presentation Synopsis: Many of the original patents on polymer, metal and ceramic additive manufacturing technology have expired. This has led to a large increase in the number of companies supplying related equipment and an associated increase in the number of companies using this technology for industrial applications. In this presentation, an overview of these technologies will be presented along with associate current and future potential industrial application. As an example, a significant amount of research work on the development of additive manufacturing has been undertaken over the last few years for fabrication of MEMS and microfluidic devices for sensing chemical and biological species. Other main applications industry areas include aerospace, automobile, and biomedical. In other recent work, the APT Research Centre at DCU is currently running projects on the development of additively manufactured dies for embossing and stamping applications, the development of metal powder for 3D printing, and the mixing of graphene and reduced graphene oxide with metal powders to produce increased strength metal matrix composites. This talk will present an overview of the capabilities and usage of the newest additive manufacturing equipment for such applications.